The supplement has no heart benefits for patients, which doesn't bode well for the drug company's efforts to market Vascepa.
Zynga is downgraded to 'neutral,' and The Fresh Market is initiated with a 'strong buy.'
Pfizer has multiple health care businesses and Elan has Tysabri royalties and a would-be acquirer.
A report questions whether the FDA will grant New Chemical Entity status for the phosphate binder.
The company's fish-oil pill is finally on pharmacy shelves 6 months after approval.
TheStreet's Adam Feuerstein gazes into his crystal ball to offer his biotechnology forecast for the new year.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
Plus, after much ado, Softbank is oh-so-close to acquiring Sprint.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
Those shackled with student loan debt are increasingly being targeted by scams and shady companies promising relief.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.